English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Traditional description of heart failure (HF) has been within the context of ischemic, hypertensive, valvular and myopathic disease. This description has contributed to the under-appreciation of HF in adult patients with congenital heart disease (CHD), who also manifest all the pathophysiological criteria constituting the clinical syndrome of HF. In adult CHD patients, heterogeneity of residual substrates predisposes them to an early development of HF, presenting a unique challenge in both categorization and protocol management of HF. As such, current diagnosis and treatment using consensus guidelines developed for HF in general remains unclear if they can serve as a meaningful framework for these patients. In this systematic review and meta-analysis, we review current evidence of this rare but life threatening form of HF affecting a large and growing number of adults. The discussion centers on clinical definition, epidemiology, pathophysiology, diagnosis and management with the view of advancing knowledge of the clinical status of HF in CHD. *Correspondence to: Aref Albakri, St-Marien hospital Bonn Venusberg, Department of Internal Medicine, Bonn, Germany, E-mail: arefalbakri@yahoo.com

medical and clinical archives

Heart failure in congenital heart disease: A review of clinical status and meta-analysis of diagnostic value of serum natriuretic peptides, and medical and device therapies